Elevian will commercialise research from Harvard and Stanford indicating young blood cells could be used to restore tissues in older patients.
Elevian, a US-based regenerative medicine developer based on research from Harvard and Stanford universities, has made its public debut with $5.5m in seed capital from investors including Stanford-StartX Fund.
Bold Capital Partners, Longevity Fund, Western Technology Investment, Kizoo Technology Ventures, Thynk Capital and unnamed additional investors have contributed to the round.
Founded in 2017, Elevian will commercialise a therapy for age-related diseases such as coronary artery disease and Alzheimer’s based on the principle that inserting young blood cells into an…
